Literature DB >> 25188399

Clinical utility of different bone marrow examination methods in the diagnosis of adults with sporadic Gaucher disease type 1.

Maciej Machaczka, Alicja Markuszewska-Kuczyńska, Sofie Regenthal, Artur Jurczyszyn, Krystyna Gałązka, Björn E Wahlin, Monika Klimkowska.   

Abstract

INTRODUCTION: In the absence of a known affected family member, frequent symptoms of Gaucher disease (GD), a rare lysosomal storage disorder, such as thrombocytopenia or splenomegaly, often lead to hematological diagnostic workup.
OBJECTIVES: The aim of the study was to compare the clinical utility of aspiration biopsy of the bone marrow (ASP) with trephine biopsy (TB) for the diagnosis of GD type 1 (GD1). PATIENTS AND METHODS: Six non-Jewish patients with sporadic GD1 were initially examined with ASP and TB to establish the cause of cytopenia and splenomegaly. In the current study, samples from each patient consisted of 2 bone marrow slides. On each slide, 500 nucleated cells were counted and then averaged. The composition of bone marrow TBs was assessed using digital images analyzed on a computer.
RESULTS: Of 6 patients, 5 carried at least 1 N370S allele with a c.1226A>G mutation in the GBA1 gene. The median number of Gaucher cells identified during cytological assessment of bone marrow smears was 4 (range, 1-18), and the median percentage of Gaucher cells was 0.4% (range, 0.1%-1.8%). The absolute proportion of Gaucher cells in histological samples ranged from 22% to 36% (median value, 28%), and the ratio of Gaucher cell infiltrate to hematopoietic tissue ranged from 34% to 54% (median value, 47%). The median value of the ratio of Gaucher cells to hematopoietic tissue was strikingly lower when using ASP compared with TB (P = 0.028).
CONCLUSIONS: Our results indicate that ASP is not a reliable diagnostic tool for the detection of GD1. Thus, patients with unclear long-lasting splenomegaly and/or thrombocytopenia, in whom bone marrow aspirate cytology is negative for Gaucher cells, should be routinely referred for an enzymatic assay for GD.

Entities:  

Mesh:

Year:  2014        PMID: 25188399     DOI: 10.20452/pamw.2493

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  2 in total

1.  Clinical Utility of Bone Marrow Study in Gaucher Disease: A Case Report of Gaucher Disease Type 3 With Intractable Myoclonic Seizures.

Authors:  John Hoon Rim; Minyoul Baik; Sun Och Yoon; Kyoung Heo; Jaewoo Song
Journal:  Ann Lab Med       Date:  2016-03       Impact factor: 3.464

2.  The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy.

Authors:  Nadia Sawicka-Gutaj; Maciej Machaczka; Izabela Kulińska-Niedziela; Jadwiga Bernardczyk-Meller; Paweł Gutaj; Jerzy Sowiński; Marek Ruchała
Journal:  Ups J Med Sci       Date:  2016-04-11       Impact factor: 2.384

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.